Search Bar & Filters
Found 3214 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are investigating the minimum effective dose of 131I-apamistamab as part of a conditioning regimen for patients with advanced sickle cell disease SCD undergoing hematopoietic stem cell transplantation. This Phase 1, single-center study focuses on patients aged 12 to 50 years with sickle cell anemia and an available HLA-matched sibling donor. The study aims to replace the typical conditioning regimen, which includes chemotherapy, total body irradiation, and Campath antibody, with 131I-apamistamab to potentially reduce long-term side effects such as secondary cancers, infertility, cataracts, and lung toxicity. Participants will receive 131I-apamistamab as an intravenous infusion approximately ten days before receiving donor stem cell infusion. The dose of 131I-apamistamab will be personalized and prepared in advance, with target dose levels of either 100 mCi or 150 mCi. Additional treatments may include oral sirolimus to suppress immune response and intravenous Campath antibody. Other procedures such as total body irradiation and red blood cell exchange transfusions may also be part of the overall treatment process, following institutional practices. During the study, participants will undergo various assessments including blood tests, hormone level measurements, and imaging scans to monitor drug absorption and treatment effects. Researchers will evaluate outcomes such as graft failure rate 42 days after transplant, event-free survival, engraftment times for neutrophils and platelets, incidence of graft-versus-host disease, transplant-related toxicities and infections, donor cell presence, and immune recovery. Hormonal evaluations related to fertility will be measured at study start and one year post-transplant. The study includes long-term follow-up of up to seven years to assess these outcomes and safety.
Actively Recruiting
Healthy Volunteer
This research aims to explore how a dietary supplement called the Insulin Balance Formula may help support healthy insulin levels and its effects on weight, fatigue, and sugar cravings. The study focuses on generally healthy adults who want to maintain healthy insulin levels and improve overall metabolic health using this nutritional approach. It is an observational study where participants act as their own control in a single-arm design to detect initial signals of benefit and gather safety data. Participants will take the Insulin Balance Formula supplement daily for 30 days, starting with one capsule to assess tolerance and increasing to three capsules, ideally one before each meal or all at once. The formula contains five ingredients Berberine, Beta Alanine, Zinc Citrate, Folate, and Fenugreek Extract. During the study, participants will follow a balanced diet and avoid introducing new supplements or health interventions. Throughout the 30-day period, participants will complete several assessments, including body composition measurement, the PROMIS Sleep Disturbance Scale, the Carbohydrate Craving Questionnaire, and evaluations of hunger and fatigue after meals. These will be done at baseline and study completion, with some hunger and fatigue assessments repeated randomly during the study. Participants are encouraged to provide honest feedback, and their privacy is protected. The study aims to generate meaningful data on how this supplement may support metabolic health and guide future research.
Actively Recruiting
Researchers are evaluating the clinical performance of 3M Filtek Supreme Flowable Composite for dental restorations, focusing on Class IV cavities and veneers on anterior maxillary teeth. This non-randomized clinical study aims to provide data on the survival and aesthetic and functional outcomes of this flowable composite material, which has been developed to improve ease of use and adaptability compared to traditional paste composites. The study includes follow-ups at 7 days, 6 months, 12 months, and 24 months, using a modified Fdration Dentaire Internationale FDI score updated in 2023 to assess the restorations. Participants will receive 3M Filtek Supreme Flowable Composite treatment applied to either Class IV restorations or veneers, with veneers performed only on paired contralateral teeth. The composite contains a mix of resins and various fillers designed for improved handling and performance. The study is conducted at a single site and includes at least 50 Class IV and 25 veneer restorations. Evaluations will be performed by two calibrated examiners different from the treating operator to ensure objective scoring. During the study, participants will have their dental restorations photographed and assessed at each follow-up visit for up to 24 months. The primary outcome is the survival of the treated site over this period. Secondary outcomes include evaluations of esthetic and functional properties. Participants must attend all scheduled follow-up visits and maintain good oral hygiene. Safety and performance data will be collected throughout the study duration, which lasts up to 24 months post-treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of psilocybin, a 5-HT2A receptor agonist, for helping adults with tobacco use disorder quit smoking. This phase 2, multi-site, double-blind, randomized clinical trial involves 66 participants across four experienced research sites. The study aims to compare psilocybin with niacin, an active placebo, both combined with cognitive behavior therapy CBT, to assess smoking cessation effectiveness and related cognitive changes over 12 months. Participants will be randomly assigned to receive either oral psilocybin or oral niacin in two sessions spaced one week apart. Psilocybin doses are 30 mg in the first session and either 30 mg or 40 mg in the second, depending on responses to a mystical experience questionnaire. Niacin doses are 150 mg in the first session and either 150 mg or 200 mg in the second, following the same dosing schedule. Both groups receive CBT alongside the medication sessions to support quitting smoking. During the study, participants will undergo assessments including cognitive control tasks and questionnaires about smoking urges at screening and shortly after a target quit date. Smoking abstinence will be biochemically confirmed and measured for up to 12 months. Safety and health status will be monitored through interviews, physical exams, ECGs, and lab tests. The trial also investigates psychological factors that may influence quitting success, with overall participation lasting about one year.
Actively Recruiting
This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drugs, 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, in men with prostate cancer that has spread and no longer responds to hormone-lowering treatments. This study focuses on cancers that express a protein called PSMA and aims to find safe and effective dosing while monitoring how the drugs behave in the body. Participants will go through different study phases. In the initial dosimetry phase, a single dose of 200 MBq of 64Cu-SAR-bisPSMA is given. Later phases involve receiving multiple doses of 64Cu-SAR-bisPSMA or 67Cu-SAR-bisPSMA, with doses and number of administrations varying by phase and participant group. The dose escalation phase tests increasing doses of 67Cu-SAR-bisPSMA, followed by a cohort expansion phase with up to six doses of the recommended 67Cu-SAR-bisPSMA dose. During the study, participants will undergo PETCT scans to track drug distribution and dosimetry within 48 hours of dosing. Researchers will measure prostate-specific antigen PSA levels and radiographic responses over up to five years to evaluate treatment effects. Safety will be monitored through assessments of vital signs, ECGs, laboratory tests, and recording any adverse events. The total study duration can extend up to five years for long-term follow-up.
Actively Recruiting
Researchers are studying the use of 68Ga-DOTATATE PETMRI imaging to improve diagnosis and management of patients with somatostatin receptor-positive central nervous system tumors. This includes meningiomas and other brain tumors such as esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and certain metastatic tumors. The study aims to determine if this imaging method better distinguishes tumor recurrence from post-treatment changes and assesses residual tumor extent, especially in challenging cases like high-grade tumors or post-radiation changes. Participants undergo a specialized hybrid Gallium-68-DOTATATE PETMRI scan instead of or alongside their standard MRI exams. This scan is performed prior to surgery for meningioma patients and may be repeated up to two times as part of standard care follow-up. For patients with other somatostatin receptor-positive CNS tumors, the PETMRI is performed during their regular MRI evaluations. In some cases where a 3 Tesla MRI is not possible, a 1.5 Tesla MRI combined with PETCT fusion imaging is used. During the study, participants have imaging sessions to assess tumor presence and changes over time, with data collected for up to 10 years. Researchers evaluate the diagnostic value of the PETMRI scans and correlate findings with tumor tissue markers such as SSTR2 expression, Ki67, progesterone receptor, and EGFR. The study is ongoing with long-term follow-up to monitor the imagings clinical benefit and support treatment decisions.
1-10 of 3,214
1